GSK acquires Elsie Biotechnologies for up to $50m to enhance oligonucleotide therapeutics
GSK plc (LSE/NYSE: GSK), a global healthcare leader, has completed the acquisition of Elsie Biotechnologies, a private biotechnology company based in San Diego, for a deal valued at up to $50 million (approximately £39 million). This acquisition marks a significant enhancement in GSK’s research and development capabilities, particularly in the promising field of oligonucleotide therapeutics. […]